<DOC>
	<DOCNO>NCT00975663</DOCNO>
	<brief_summary>The purpose study evaluate lung heart-lung transplant patient tacrolimus mycophenolate impact optimize mofetil ( MMF ) therapeutic drug monitoring dose adjustment drug incidence treatment failure first three year post-transplantation .</brief_summary>
	<brief_title>Bayesian Dose Adjustment Immunosuppressants After Lung Transplantation</brief_title>
	<detailed_description>This research base prospective randomize trial compare optimize TDM tacrolimus MMF current strategy tacrolimus MMF dose adjustment lung transplant recipient . The study focus first three year post-transplantation , treatment failure ( include BOS ) occur mainly post-transplantation period . As aim tacrolimus MMF dose individualization avoid over- underexposure , purpose study treatment failure composite criterion gather event reflect over- underexposure tacrolimus MMF . Optimized TDM tacrolimus MMF base blood tacrolimus plasma MPA AUC Bayesian estimation compare current strategy : tacrolimus dose adjustment base trough level ( C0 ) administration standard dose MMF , decrease pulmonologist case adverse drug reaction increase case inefficacy . The efficacy optimize strategy vs. current strategy mainly evaluate incidence treatment failure .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Inclusion Criteria Male female patient age 18 year CF nonCF patient receive singlelung doublelung heartlung transplantation first time Patients oral tacrolimus MMF least 48 hour time inclusion ( administration via nasogastric tube possible necessary ) Patients without progressive chronic pathology jeopardize short term patient graft survival Patients accept comply least evaluation visit plan investigation center first three year posttransplantation ( D7 , D14 , M1 , M3 , M6 , M12 , M18 , M24 , M30 , M36 ) Patients give free inform write consent participate study Patients health insurance policy register health insurance program Patients age less 18 year patient 18 year guardianship Patients disagree research Patients contraindication receive tacrolimus MMF Patients cyclosporine , sirolimus everolimus Patients already benefit solid organ transplantation past ( include lung heartlung transplantation ) Patients infected Burkholderia cenocepacia ( Burkholderia cepacia genomovar III ) Patients receive HIV protease inhibitor ( major pharmacokinetic interaction tacrolimus ) Pregnant breastfeed woman childbearing age use efficient contraceptive method Drug user patient suffer neuropsychiatric disorder prevent proper comprehension protocol reliable consent Patients already participate another interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Lung transplantation</keyword>
	<keyword>heart-lung transplantation</keyword>
	<keyword>therapeutic drug monitoring</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>mycophenolate</keyword>
	<keyword>immunosuppressant</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>